Menu
Skip to content

Press Releases

Filter Releases
 

Albireo has been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)

Nov 4, 2012

Gothenburg, Sweden, November 8, 2012– Albireo AB (Gothenburg, Sweden; “Albireo”), a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter; IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration...
Page: First Previous Next Last
 

Albireo Homepage